• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23675 Records] Selected Records [0 Hits] [Clear]
Year Source Title
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of older patients with acute myeloid leukemia by hematopoietic growth factor combined with chemotherapy- primary research
1995     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treatment of obstructive sleep apnea: an overview - nonsystematic review
2005     Institute for Clinical Systems Improvement (ICSI) Treatment of obesity in children and adolescents
2015     Agency for Healthcare Research and Quality (AHRQ) Treatment of nonmetastatic muscle-invasive bladder cancer
2020     Swiss Federal Office of Public Health (FOPH) Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitor therapy
1995     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of neurogenic bladder dysfunction - primary research
2000     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of neck complaints - primary research
2007     Haute Autorite de sante (HAS) Treatment of multiple missing teeth in children with rare diseases by implant placement
2001     Norwegian Knowledge Centre for the Health Services (NOKC) Treatment of lumbar disc herniation
2004     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of lower limbs arteriopathy
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of low back pain - primary research
2001     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of localised prostate cancer
2004     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of leg varices
2010     The Swedish Council on Health Technology Assessment (SBU) Treatment of insomnia in adults
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treatment of inoperable advanced non-small-cell lung cancer: regimens with or without taxane
2009     Norwegian Knowledge Centre for the Health Services (NOKC) Treatment of infantile colic
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of hydromyelia in adults: a review of clinical effectiveness and guidelines
2023     NIHR Health Technology Assessment programme Treatment of Hidradenitis Suppurativa Evaluation Study: the THESEUS prospective cohort study
2011     The Swedish Council on Health Technology Assessment (SBU) Treatment of hemophilia A and B and von willebrand disease
2005     Medical Services Advisory Committee (MSAC) Treatment of heart failure by permanent tri-chamber synchronisation (#1042)
2007     Haute Autorite de sante (HAS) Treatment of hearing loss by cochlear implantation or auditory brain stem implantation
2019     NIHR Health Technology Assessment programme Treatment of first-time traumatic anterior shoulder dislocation UK.TASH-D Study
2002     NIHR Health Technology Assessment programme Treatment of established osteoporosis: a systematic review and cost-utility analysis
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of diffuse systemic sclerosis with photopheresis - primary research
2020     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment of depression with transcranial magnetic stimulation using an H-coil (dTMS)
2020     Agency for Healthcare Research and Quality (AHRQ) Treatment of depression in children and adolescents
1999     Agency for Healthcare Research and Quality (AHRQ) Treatment of depression - newer pharmacotherapies
2004     The Swedish Council on Health Technology Assessment (SBU) Treatment of depression
2001     Agency for Healthcare Research and Quality (AHRQ) Treatment of degenerative lumbar spinal stenosis - Volume 1. Evidence report; Volume 2. Evidence tables and bibliography
1999     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of cranio-mandibular dysfunction - primary research
1997     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of constipation in children with biofeedback-training - primary research
2009     Agency for Healthcare Research and Quality (AHRQ) Treatment of common hip fractures
2003     Agency for Healthcare Research and Quality (AHRQ) Treatment of coexisting cataract and glaucoma
2015     NIHR Health Technology Assessment programme Treatment of childhood anxiety disorder in the context of maternal anxiety disorder: a randomised controlled trial and economic analysis
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Treatment of carpal tunnel syndrome - primary research
1995     Australian Health Technology Advisory Committee (AHTAC) Treatment of benign prostatic hyperplasia in Australia - some economic considerations
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of autism
1999     Agency for Healthcare Research and Quality (AHRQ) Treatment of attention-deficit/hyperactivity disorder
2013     Agency for Healthcare Research and Quality (AHRQ) Treatment of atrial fibrillation
2005     The Swedish Council on Health Technology Assessment (SBU) Treatment of anxiety disorders: a systematic review
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of anemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens with or without protease inhibitors: a review of the clinical evidence
2001     The Swedish Council on Health Technology Assessment (SBU) Treatment of alcohol and drug abuse - an evidence-based review
2001     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Treatment of age related macular degeneration
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Treatment Foster Care Oregon for seriously delinquent adolescents
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for restless legs syndrome
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for hepatitis C virus infection in adults
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for glaucoma: comparative effectiveness
2008     NIHR Health Technology Assessment programme Treatment for fibroids: Uterine Artery Embolisation (UAE) or hysterectomy (HOPEFUL) - Primary Research (e.g. trial)
2012     Agency for Healthcare Research and Quality (AHRQ) Treatment for depression after unsatisfactory response to SSRIs
2010     Institute of Health Economics (IHE) Treatment for convicted adult male sex offenders
2018     Agency for Healthcare Research and Quality (AHRQ) Treatment for bipolar disorder in adults: a systematic review
2017     Agency for Healthcare Research and Quality (AHRQ) Treatment for adults with schizophrenia
2019     Agency for Healthcare Research and Quality (AHRQ) Treatment for acute pain: an evidence map
2024     Swiss Federal Office of Public Health (FOPH) Treatment duration of trastuzumab in early HER2-positive breast cancer
2011     Health Council of the Netherlands Gezondheidsraad (GR) Treating the effect of child abuse
2002     Norwegian Knowledge Centre for the Health Services (NOKC) Treating prostate cancer with brachytherapy
2003     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Treating osteoporosis with teriparatide: many unknowns?
2003     University of York Treating nocturnal enuresis in children
2001     The Swedish Council on Health Technology Assessment (SBU) Treating influenza by medication - zanamivir - early assessment briefs (ALERT)
1999     University of York Treating head lice and scabies
2000     The Swedish Council on Health Technology Assessment (SBU) Treating asthma and COPD - a systematic review
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Travoprost (Travatan®)
2016     The Swedish Council on Health Technology Assessment (SBU) Traumatic shaking – The role of the triad in medical investigations of suspected traumatic shaking
2011     Agency for Healthcare Research and Quality (AHRQ) Traumatic brain injury and depression.
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab-DM1 (Herceptin-DM1) for breast cancer, locally advanced or metastatic, HER2 positive - second or third line
2011     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab SC (Herceptin SC) for breast cancer, early or metastatic, HER2 positive - monotherapy or combination therapy, including neo-adjuvant and adjuvant use
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2009     NIHR Health Technology Assessment programme Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2010     National Institute for Health and Care Excellence (NICE) Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. NICE technology appraisal guidance 208
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011     NIHR Health Technology Assessment programme Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2006     Quality Improvement Scotland (NHS QIS ) Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Trastuzumab for breast cancer treatment
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2017     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2020     National Institute for Health and Care Excellence (NICE) Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2013     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2021     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2023     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2024     National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2023     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2005     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2003     ECRI Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trastuzumab (Herceptin®)
2006     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2007     HAYES, Inc. Trastuzumab (Herceptin) for metastatic cancer
2001     The Swedish Council on Health Technology Assessment (SBU) Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2010     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2012     NIHR Horizon Scanning Centre (NIHR HSC) Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2007     HAYES, Inc. Trastuzumab (Herceptin) for early breast cancer